Currently the phase 2b multinational clinical trial (CENTAUR) is underway to evaluate the anti-inflammatory and anti-fibrotic potential of a dual CCR2/CCR5 antagonist Cenicriviroc (CVC) in patients with NASH[10]. Here, CCR5 is linked to metabolic dysfunction-associated steatohepatitis.